All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Phase III results of vunakizumab for moderate-to-severe chronic plaque psoriasis
By Ella Dixon
|
Vunakizumab, a novel anti-IL-17A monoclonal antibody, was investigated in a randomized, double-blind phase III trial (NCT04839016) for treating moderate-to-severe chronic plaque psoriasis.1 The trial enrolled 690 patients, who were randomized 2:1 to receive either vunakizumab 240 mg (n = 461) or placebo (n = 229) over 12 weeks, followed by a maintenance period of up to 52 weeks. The co-primary endpoints were the proportion of patients achieving PASI 90 and a sPGA 0/1 score at Week 12.1 |
| Key learnings |
| At Week 12, a higher proportion of patients treated with vunakizumab vs placebo achieved PASI 90 and sPGA 0/1 (76.8% vs 0.9% and 71.8% vs 0.4%, respectively; p<0.0001). Efficacy was maintained through Week 52 with continuous vunakizumab. |
| Median time to PASI 90 response was 8.3 weeks in the vunakizumab group and was not reached in the placebo group. At 12 weeks, a higher proportion of patients in the vunakizumab group showed improved HR-QoL by achieving DLQI 0/1 compared with placebo (62.0% vs 12.1%). |
| The incidence of AEs in the first 12 weeks was similar between the vunakizumab and placebo groups (69.1% vs 71.6%). Serious treatment-related AEs occurred in 0.9% of patients in the vunakizumab group compared with none in the placebo group. No new safety signals were observed with continuous treatment with vunakizumab up to 52 weeks. |
| Vunakizumab demonstrated rapid, deep, and durable responses with favorable tolerability, offering a promising therapeutic option for chronic plaque psoriasis, comparable with other IL-17A inhibitors. The safety and efficacy of vunakizumab compared with other approved therapies for psoriasis require further investigation. |
Abbreviations: AE, adverse event; DLQI, dermatology life quality index; HR-QoL, health-related quality of life; IL, interleukin; PASI 90, 90% improvement in Psoriasis Area and Severity Index; sPGA, Static Physician's Global Assessment.
- Yan K, Li F, Bi X, et al. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2024. Online ahead of print. DOI: 1016/j.jaad.2024.09.031
More about...
Your opinion matters
6 votes - 3 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox